The Asia-Pacific region is seeing a sharp increase in cardiovascular diseases (CVDs), influenced by lifestyle shifts, urbanization, and a growing elderly population. Rising sedentary behaviors, poor diets, smoking, alcohol use, and stress are contributing to higher obesity rates and conditions like hypertension, diabetes, and dyslipidemia, all of which increase CVD risk. In addition, with one of the world’s fastest-aging populations, age-related vulnerabilities to heart disease are more common. These trends are transforming healthcare needs and driving demand for interventional cardiology and vascular devices to manage and treat CVDs effectively.
The interplay of lifestyle changes, an aging population, heightened awareness, and technological innovations is expected to sustain and enhance the demand for interventional devices. As healthcare providers continue to prioritize cardiovascular health and invest in advanced treatment solutions, the market for interventional cardiology and peripheral vascular devices is projected to grow substantially, addressing the urgent healthcare needs posed by the increasing burden of cardiovascular diseases in the region
Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-interventional-cardiology-peripheral-vascular-devices-market
Data Bridge Market Research analyzes that the Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices Market is expected to grow at a CAGR of 8.4% in the forecast period of 2024 to 2031 and is expected to reach USD 5.16 billion by 2031.
Key Findings of the Study
Growing Geriatric Population
The growing geriatric population in the Asia-Pacific region is a significant driver of the interventional cardiology and peripheral vascular devices market. As older adults age, the prevalence of cardiovascular diseases (CVDs) rises, necessitating specialized medical devices to address their unique needs. Older adults are particularly susceptible to CVDs due to age-related changes and risk factors like hypertension, diabetes, and hyperlipidemia, increasing the demand for interventional devices such as stents and catheters. Furthermore, the elderly population's growth is leading to a rise in demand for invasive procedures and a proactive approach to cardiovascular health, enhancing the utilization of diagnostic and therapeutic devices and driving market expansion.
As the number of elderly individual’s increases, so does the prevalence of cardiovascular diseases, which results in heightened demand for specialized medical devices and interventional procedures. With an emphasis on preventive healthcare and ongoing technological innovations, the market is expected to experience substantial growth, effectively addressing the unique healthcare needs of the aging population and improving patient outcomes in cardiovascular care.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Product (Angioplasty Balloons, Stent, Catheters, Aneurysm Repair Products, and Others and Accessories), Type (Conventional and Standard), Procedure (Peripheral Angioplasty, Iliac Intervention, Tibial (Below-The-Knee) Interventions, Arterial Thrombectomy, Peripheral Atherectomy, and Femoropopliteal Interventions), Indication (Peripheral Arterial Disease and Coronary Intervention), Age Group (Geriatric, Adults, and Pediatric ) End User (Hospitals, Ambulatory Surgery Centers, Nursing Facilities, Clinics and Others.), Distribution Channel (Third Party Distributors, Direct Tender, and Others)
|
|
Countries Covered
|
China, India, Japan, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Abbott (U.S.), Boston Scientific Corporation (U.S.), BD (U.S.), Medtronic (U.S.), Terumo Corporation (Japan), B.Braun SE (Germany), ENDOCOR GmbH & CO. KG (Germany), Teleflex Incorporated (U.S.), Lepu Medical Technology (Beijing)Co.,Ltd. (China), MicroPort Scientific Corporation (China), Koninklijke Philips N.V. (Netherlands), Biotronik (Germany), SMT (China), OrbusNeich Medical Group Holdings Limited (China), Biosensors International Group, Ltd. (Singapore), Edwards Lifesciences Corporation (U.S.), AngioDynamics (U.S.), Alvimedica (Turkey), Cook (U.S.), Cordis (U.S.), Palex (Spain), and W. L. Gore & Associates (U.S.), Inc.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
Asia-Pacific interventional cardiology and peripheral vascular devices market is segmented into seven notable segments which are based on product, type, procedure, indication, age group, end user, and distribution channel.
- On the basis of product, the market is segmented into angioplasty balloons, stents, catheters, aneurysm repair products, and others and accessories
In 2024, the angioplasty balloons segment is expected to dominate the market
In 2024, the angioplasty balloons segment is expected to dominate the Asia-Pacific interventional cardiology and peripheral vascular devices market with a market share of 28.36% due to increase in cases of peripheral arterial diseases, increased risk of sedentary lifestyle, early diagnosis, and detection of the peripheral arterial diseases by the peripheral vascular devices, rise in government funding and presence of reimbursement policies in healthcare.
- On the basis of type, the market is segmented into conventional and standard
In 2024, the conventional segment is expected to dominate the market
In 2024, the conventional segment is expected to dominate the market with a market share of 56.44% due to rising prevalence of cardiovascular diseases such as coronary artery diseases, carotid artery diseases, ischemic heart diseases, congenital heart abnormalities, and others.
- On the basis of procedure, the market is segmented into peripheral angioplasty, iliac intervention, tibial (below-the-knee) interventions, arterial thrombectomy, peripheral atherectomy, and femoropopliteal interventions. In 2024, the peripheral angioplasty segment is expected to dominate the Asia-Pacific interventional cardiology and peripheral vascular devices market with a market share of 30.00%.
- On the basis of indication, the market is segmented into peripheral arterial disease and coronary intervention. In 2024, the peripheral arterial disease segment is expected to dominate the Asia-Pacific interventional cardiology and peripheral vascular devices market with a market share of 64.94%
- On the basis of age group, the market is segmented into geriatric, adults, and pediatric. In 2024, the geriatric segment is expected to dominate the Asia-Pacific interventional cardiology and peripheral vascular devices market with a market share of 75.46%
- On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, nursing facilities, clinics, and others. In 2024, the hospitals segment is expected to dominate the Asia-Pacific interventional cardiology and peripheral vascular devices market with a market share of 59.65%
- On the basis of distribution channel, the market is segmented into third party distributors, direct tender, and others. In 2024, the direct tender segment is expected to dominate the Asia-Pacific interventional cardiology and peripheral vascular devices market with a market share of 65.98%
Major Players
Data Bridge Market Research analyzes Abbott (U.S.), Boston Scientific Corporation (U.S.), BD (U.S.), Medtronic (U.S.), and Terumo Corporation (Japan) as the major market players of the market.
Market Development
- In September 2024, Abbott and Seed Global Health are partnering to enhance maternal and child healthcare in Malawi. Their initiative includes establishing a Maternal Health Center of Excellence at Queen Elizabeth Central Hospital, focusing on training health workers to improve care quality and sustainability
- In September 2024, BD completed its acquisition of Edwards Lifesciences' Critical Care product group, renaming it BD Advanced Patient Monitoring. This move expanded BD's portfolio with advanced monitoring technologies and AI-enabled clinical tools, enhancing its smart connected care solutions and supporting future innovations in patient care
- In March 2024, Medtronic has received FDA approval for its latest Evolut FX+ TAVR system, designed to treat symptomatic severe aortic stenosis. This new generation features a modified diamond-shaped frame that offers larger coronary access windows, enhancing catheter maneuverability while maintaining the exceptional valve performance and strength associated with the Evolut platform
- In March 2024, Abbott has extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-27 season, focusing on combating childhood malnutrition and promoting healthy habits. The collaboration has provided extensive nutrition education and screening for millions of children worldwide
- In November 2023, Boston Scientific Corporation concluded its acquisition of Relievant Medsystems on November 17, 2023, adding the Intracept Intraosseous Nerve Ablation System to its chronic pain portfolio. The acquisition, costing USD 850 million upfront plus contingent payments, expands access to vertebrogenic pain treatment through national coverage, benefiting over 150 million lives
- In November 2023, BD and Bio Farma signed a memorandum of understanding to combat tuberculosis in Indonesia by providing access to BD's TB diagnostics. This collaboration aimed to optimize the supply chain and enhance TB diagnosis, aligning with Indonesia’s goal to eliminate the disease by 2030
- In September 2023, Boston Scientific Corporation announced it had entered into an agreement to acquire Relievant Medsystems, Inc.for USD 850 million upfront, plus contingent payments. The acquisition, expected to close in early 2024, aimed to enhance Boston Scientific's chronic low back pain treatment portfolio with the Intracept system
Regional Analysis
Geographically, the countries covered in the Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices market report are the China, India, Japan, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, and Rest of Asia-Pacific.
As per Data Bridge Market Research analysis:
China is the dominant country in the Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices market during the forecast period of 2024 to 2031
China is expected to dominate the market due to its large aging population, high prevalence of cardiovascular diseases, and increased government investments in healthcare infrastructure and technology.
For more detailed information about the Asia-Pacific Interventional Cardiology And Peripheral Vascular Devices market report, click here – https://www.databridgemarketresearch.com/reports/asia-pacific-interventional-cardiology-peripheral-vascular-devices-market
